The SGLT2i class of medications are increasingly used by physicians in Canada due to their multiple positive effects – long term survival, morbidity, and mortality rates of patients with complex medical conditions. Nevertheless, there remain unanswered questions. The results from the EMPA-KIDNEY trials will provide further insight on the effect of these drugs, and how the SGLT2is can be integrated into Canadian care moving forward. This educational lesson aims to incorporate the latest trial data findings and present these to the Canadian nephrology and endocrinology audience for quick dissemination.
Learning Objectives:
- Review the evolving reno-protective role of the SGLT2is (Medical Expert, Scholar)
- Analyze the results of the EMPA-KIDNEY trial and discuss how they align with previous CKD trials, exploring their implications for clinical practice (Medical Expert, Scholar)
- Identify what gaps remain and how emerging data will influence how specialists manage CKD, particularly in patients with T2D (Communicator, Leader)
This activity is an Accredited Group Learning (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by The Canadian Society of Nephrology. You may claim a maximum of 1.5 hours (credits are automatically calculated in MAINPORT).
Agenda:
|
30 minutes |
Arrival & Dinner Service |
|
5 minutes |
Welcome & Introductions |
|
15 minutes |
The evolution of SGLT2is |
|
5 minutes |
SGLT2is Mechanisms of Action: Current Understanding and Evolving Theories |
|
20 minutes |
Overview of EMPA-KIDNEY Results |
|
25 minutes |
Putting it All Together: What We Know Now and What Remains Undiscovered |
|
30 minutes |
Q&A : How Do EMPA-KIDNEY Results Change Nephrology Care Considerations |
|
5 minutes |
Closing Remarks and Evaluations |
Event Registration
901 Rue du Square-Victoria
Montréal, QC
H2Z 1R1
Presentation: 7:00pm-8:45pm
This event will be held primarily in French, with simultaneous interpretation services and devices for attendees who require it. (French to English and English to French available)
Faculty Presenters:
- (Moderator and Speaker) Dr. Normand Proulx MD, FRCPC (Québec)
- Dr. David Cherney MD, CM, PhD, FRCPC (Ontario)
- Dr. Stavroula Christopoulos MD, FRCPC (Québec)
Zoom weblink to be emailed to registrants a few days before the session
This event will be held primarily in French, with phone-in simultaneous interpretation services for attendees who require it. (French to English and English to French available)
Faculty Presenters:
- (Moderator and Speaker) Dr. Normand Proulx MD, FRCPC (Québec)
- Dr. David Cherney MD, CM, PhD, FRCPC (Ontario)
- Dr. Stavroula Christopoulos MD, FRCPC (Québec)
Program Faculty
| Planning Committee Member | Disclosures | |
|---|---|---|
| JORDAN WEINSTEIN MD, FRCPC CPD Network Representative (Physician Organization) Associate Professor of Medicine University of Toronto Nephrologist, St. Michael’s Hospital Director, UKidney.com Toronto, ON | Dr. Weinstein received research funding, honoraria, as well as served on advisory boards and as a speaker, for CPD Network Association, BI-Lilly, Alexion, Merck, Amgen, Janssen, Otsuka, AstraZeneca, and Bayer. |
| ALICE Y.Y CHENG MD, FRCPC Endocrinologist Trillium Health Partners and Unity Health Toronto Associate Professor, Department of Medicine University of Toronto Toronto, Ontario | Any direct financial payments including receipt of honoraria: Abbott, Amgen, Astra Zeneca, Bausch, Bayer,
Boehringer Ingelheim, Dexcom, Eli Lilly, GSK,
HLS Therapeutics, Insulet, Janssen,
Medtronic, Merck, Novo Nordisk, Pfizer,
Sanofi, Takeda, Antibody, EOCI, Six Degrees,
Liv, CPD Network, Canadian Collaborative
Research Network, Master Clinical Alliance,
Canadian Medical & Surgical Knowledge
Translation Research Group, Sea Courses,
Alliance of Best Practices in Health Education,
Partners in Progressive Medical Education,
Agence Unik, MD Briefcase, LMC Physician
Inc., Meducomm, Humber Hospital, Timed
Right, The ACADEMY More
Membership on advisory boards or speakers’ bureaus: Abbott, Amgen, Astra Zeneca, Bausch, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, GSK, HLS Therapeutics, Insulet, Janssen, Medtronic, Merck, Novo Nordisk, Pfizer, Sanofi, Takeda Funded grants or clinical trials: Applied Therapeutics, Sanofi |
| ADEERA LEVIN MD, FRCPC, FCAHS, OC Head, Division of Nephrology Professor of Medicine University of British Columbia Executive Director BC Renal Medical Lead Integration Clinical and Academic Network PHC Vancouver, BC | Membership on advisory boards
or speakers’ bureaus: Boeingher Ingleheim, Astra Zeneca, Janssen Funded grants or clinical trials: Boeingher Ingleheim, Astra Zeneca, Janssen, GSK, BI, AZ, GSK, Janssen, Chinook Steering committee and chair of various DSMB: BI, AZ, GSK, Janssen, Chinook NIH, CIHR |
| NORMAND PROULX MD, FRCPC Nephrologist CISSS de l'Outaouais, Pavillon de Hull Gatineau, QC Part Time Lecturer, McGill University Gatineau, QC | Membership on advisory boards
or speakers’ bureaus: Janssen, Otsuka, AstraZeneca, Bayer, GSK CPD Network, Novo Nordisk |
